Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine −

NeuroThera Labs Announces C$5,000,000 Private Placement of Units

Pre-revenue neurology and cannabis-tech company raises capital at a discount to fund operations and settle parent company debt.

By The Northwire Desk — AI Analysis Jun 30, 2026 · 18:00 NTLX · 0.17 NeuroThera Labs Inc.
Executive Summary
  • NeuroThera Labs Inc. announced a non-brokered private placement of up to 37,050,000 units at C$0.135 per unit, targeting gross proceeds of approximately C$5,000,000.
  • Each unit consists of one common share and one transferable common share purchase warrant.
  • Warrants are exercisable at C$0.18 per share for a 24-month term.
  • Proceeds are designated for general working capital, evaluation of prospective transactions, settlement of liabilities, and repayment of indebtedness to parent company SciSparc Ltd.
  • Closing is subject to TSX Venture Exchange approval and standard regulatory conditions.
  • Securities carry a statutory hold period of four months and one day.
Material Impact
  • The financing is dilutive, introducing ~37 million new shares and an equal number of warrants to the capital structure.
  • The placement price of C$0.135 represents a ~20% discount to the recent trading range of $0.16–$0.18, which typically pressures the stock downward toward the placement price in the short term.
  • The warrant strike price of $0.18 is currently out-of-the-money, limiting immediate secondary dilution from warrant exercises.
  • Use of proceeds to repay debt to SciSparc Ltd. highlights a related-party funding dynamic, reducing the company's independent cash runway but alleviating immediate liquidity pressure.
  • The transaction does not alter the company's pre-revenue status or commercial pipeline timeline. It is a standard survival financing for a micro-cap biotech.
NTLX · Price
Company Overview
  • NeuroThera Labs Inc. is a pre-revenue biotechnology company focused on neurology, pain management, and cannabinoid-based therapeutics.
  • Core pipeline includes MEAI+PEA combination therapies for depression, obesity, and addiction, developed in collaboration with Clearmind Medicine.
  • The company also holds patents for cannabinoid-antibiotic combinations targeting antimicrobial resistance (MRSA) and opioid-PEA formulations for pain relief.
  • In June 2026, the company closed the acquisition of a majority stake in CliniQuantum Ltd., a quantum simulation and Monte Carlo methods firm aimed at accelerating clinical trial data analysis.
  • The company is effectively controlled by SciSparc Ltd., which acquired a ~75% stake via a reverse takeover in October 2025.
Read the original news release →

More from NeuroThera Labs Inc.

Jun 03, 2026 · 17:15

Neurothera Closes Cashless Quantum-Tech Acquisition, But Dilution and Clinical Stage Risks Keep Upside Capped

M&A / Property May 27, 2026 · 08:00

Neurothera Labs Confirms Acquisition Closing Amidst Significant Equity Dilution and Regulatory Scrutiny

M&A / Property Mar 16, 2026 · 07:31

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

M&A / Property Mar 11, 2026 · 07:30

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Other Mar 10, 2026 · 07:30

Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.

M&A / Property Feb 02, 2026 · 08:00

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

M&A / Property